MDC PHARMACOKINETICS (PK) II PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://mdcpk2.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. Using allometric scaling with BW^0.75, estimate human CL for a 70 kg person given a 10 kg animal with CL = 3 L/h.

A. 6.5 L/h

B. 9.8 L/h

C. 24.2 L/h

D. 12.9 L/h

2. What are the typical effects of enterohepatic recirculation on the concentration-time profile?

A. Shortens half-life and causes a single sharp peak

B. Eliminates first-pass metabolism

C. Creates secondary peaks, prolongs apparent half-life, and extends drug exposure

D. Reduces overall exposure

3. Which factor can cause displacement leading to changes in fu?

A. Temperature

B. Dose

C. Competing drugs

D. Route of administration

4. Why is the apparent volume of distribution often larger than total body water for many drugs?

A. Increased plasma volume.

B. Vd is always equal to body water.

C. Tissue binding and sequestration into tissues raises apparent volume of distribution.

D. High renal clearance reduces Vd.

5. In obesity, for a lipophilic drug, how would the volume of distribution and loading dose change compared with a non-obese individual?

A. Vd decreases; loading dose decreases.

B. Vd increases; loading dose increases proportional to Vd.

C. Vd remains unchanged; loading dose unchanged.

D. Vd increases; loading dose decreases.

SAMPLE

6. When optimizing AUC/MIC targets for antifungal therapy, which data quality is essential?

A. MIC data accuracy

B. PK variability

C. Dose history only

D. When to draw troughs

7. To maintain a target Css with IV infusion, what is the maintenance dosing rate?

A. Rate_in = Css / Cl

B. Rate_in = Cl × Css

C. Rate_in = Vd × Css

D. Rate_in = Cl / Css

8. Clarithromycin belongs to which antibiotic class?

A. Macrolides

B. Cephalosporin

C. Penicillin

D. Quinolones

9. In the well-stirred hepatic clearance model, if fu*CLint is much smaller than Qh, the hepatic clearance CLh is approximately equal to which quantity?

A. fu*CLint

B. Qh

C. fu*CLint + Qh

D. Qh - fu*CLint

10. Which drug is listed under Other Antibiotics in the material?

A. Amoxicillin

B. Ofloxacin

C. Minocycline

D. Rifampicin

SAMPLE

Answers

SAMPLE

1. D
2. C
3. C
4. C
5. B
6. A
7. B
8. A
9. A
10. D

SAMPLE

Explanations

SAMPLE

1. Using allometric scaling with BW^0.75, estimate human CL for a 70 kg person given a 10 kg animal with CL = 3 L/h.

A. 6.5 L/h

B. 9.8 L/h

C. 24.2 L/h

D. 12.9 L/h

Allometric scaling of clearance uses body weight raised to the 0.75 power to account for size differences in how drugs are cleared across species. The human clearance is estimated from an animal value by multiplying by the weight ratio to the 0.75 power: CL_human = CL_animal × (BW_human / BW_animal)^0.75. Here, CL_animal is 3 L/h from a 10 kg animal, and you're scaling to a 70 kg human. So CL_human ≈ 3 × (70/10)^0.75 = 3 × 7^0.75. Calculating 7^0.75 gives about 4.3, so CL_human ≈ 3 × 4.3 ≈ 12.9 L/h. Thus the estimated human clearance is about 12.9 L/h. Using different exponents would yield other numbers (e.g., 7^1 would give 21 L/h), but 0.75 is the standard exponent used for clearance scaling.

2. What are the typical effects of enterohepatic recirculation on the concentration-time profile?

A. Shortens half-life and causes a single sharp peak

B. Eliminates first-pass metabolism

C. Creates secondary peaks, prolongs apparent half-life, and extends drug exposure

D. Reduces overall exposure

Enterohepatic recirculation is when drug molecules that are excreted into bile are released back into the gut and then reabsorbed into the bloodstream. This reentry acts as a second input of drug after the initial absorption, which often shows up as a second peak on the concentration-time curve. Because the drug returns to systemic circulation after biliary excretion, the apparent elimination half-life is longer and the overall exposure (AUC) is extended due to these additional absorption cycles. The timing and size of the secondary peak depend on how quickly bile is released, gut transit, and whether gut bacteria can cleave conjugates to regenerate the active drug. So, enterohepatic recirculation creates secondary peaks, prolongs the apparent half-life, and extends drug exposure. It does not eliminate first-pass metabolism, and it can increase exposure rather than reduce it, through recycling.

3. Which factor can cause displacement leading to changes in fu?

A. Temperature

B. Dose

C. Competing drugs

D. Route of administration

Displacement in plasma protein binding happens when two drugs compete for the same binding sites on proteins like albumin. The unbound fraction (fu) is the part of a drug that is free to distribute into tissues and be cleared. When a second drug with affinity for those sites is present, it can push the first drug off the sites, increasing fu. That rise in fu can then alter distribution and clearance of the displaced drug. Competing drugs are the factor that directly cause this displacement. Temperature can tweak binding a bit, but it's not the typical driver of displacement in clinical PK. Dose can change overall levels and, at very high concentrations, may saturate binding sites, but that's not the same mechanism as competitive displacement. Route of administration doesn't cause displacement in binding.

SAMPLE

4. Why is the apparent volume of distribution often larger than total body water for many drugs?

A. Increased plasma volume.

B. Vd is always equal to body water.

C. Tissue binding and sequestration into tissues raises apparent volume of distribution.

D. High renal clearance reduces Vd.

The key idea is that apparent volume of distribution reflects how widely a drug distributes beyond the plasma. If most of the drug leaves the blood and resides in tissues or binds strongly to tissue components, the plasma concentration for a given dose drops. Since Vd = Dose divided by the plasma concentration, extensive tissue distribution makes this ratio large. That tissue binding and sequestration into various tissues (often driven by lipophilicity and affinity for tissue components) pushes the apparent Vd above total body water. Other options don't fit as well because plasma volume expansion affects the circulating fluid compartment but doesn't explain large tissue distribution; Vd is not fixed to body water for all drugs; and renal clearance relates to elimination, not the extent of distribution.

5. In obesity, for a lipophilic drug, how would the volume of distribution and loading dose change compared with a non-obese individual?

A. Vd decreases; loading dose decreases.

B. Vd increases; loading dose increases proportional to Vd.

C. Vd remains unchanged; loading dose unchanged.

D. Vd increases; loading dose decreases.

Lipophilic drugs spread into fat tissue, so in obesity the expanded fat mass increases the apparent volume of distribution. When you want to rapidly reach a target plasma concentration, the loading dose is calculated as LD = Vd × target concentration. If Vd increases, the loading dose must increase in proportion to reach the same target concentration. So in obesity, for a lipophilic drug, both Vd and the loading dose increase proportionally.

6. When optimizing AUC/MIC targets for antifungal therapy, which data quality is essential?

A. MIC data accuracy

B. PK variability

C. Dose history only

D. When to draw troughs

The essential data quality is the accuracy of the MIC measurement. AUC/MIC is a PK/PD index that ties the drug exposure (AUC) to the organism's susceptibility (MIC). If the MIC value is incorrect, the calculated AUC/MIC target will be misinterpreted, leading to inappropriate dosing decisions. Accurate MIC data—obtained with standardized, reliable laboratory methods and consistent procedures—ensures the target reflects the true vulnerability of the pathogen. PK variability and when troughs are drawn affect how well you can achieve or verify the target in a patient, but they don't define the target itself. Dose history helps estimate exposure, but without a correct MIC, the AUC/MIC ratio you're aiming for could be off.

SAMPLE

7. To maintain a target Css with IV infusion, what is the maintenance dosing rate?

A. Rate_in = Css / Cl

B. Rate_in = Cl × Css

C. Rate_in = Vd × Css

D. Rate_in = Cl / Css

Maintaining a target plasma concentration during IV infusion comes down to balancing what goes in with what comes out. At steady state, the rate of drug entering the body equals the rate of drug being eliminated. The rate of elimination is the product of clearance and the target concentration, so the maintenance infusion rate must be Cl × Css. In other words, you inject at a rate that matches how quickly the drug is cleared at the desired concentration. Volume of distribution, Vd, affects how long it takes to reach Css, not the amount you must infuse per unit time to keep Css steady. The other expressions don't fit because they either mix units incorrectly or represent total amount rather than a rate.

8. Clarithromycin belongs to which antibiotic class?

A. Macrolides

B. Cephalosporin

C. Penicillin

D. Quinolones

The main idea here is recognizing how antibiotics are categorized by their mechanism of action. Clarithromycin is a macrolide antibiotic. Macrolides bind to the 50S ribosomal subunit and block the translocation step in protein synthesis, which stops bacteria from producing essential proteins and slows or halts their growth. This places clarithromycin with other macrolides like erythromycin and azithromycin. In contrast, cephalosporins and penicillins are beta-lactam antibiotics that disrupt cell wall synthesis, and quinolones inhibit DNA gyrase and topoisomerase IV. So the correct classification is macrolides.

9. In the well-stirred hepatic clearance model, if fu*CLint is much smaller than Qh, the hepatic clearance CLh is approximately equal to which quantity?

A. fu*CLint

B. Qh

C. fu*CLint + Qh

D. Qh - fu*CLint

In the well-stirred hepatic clearance model, the clearance is determined by both liver blood flow and intrinsic clearance, with only the unbound drug being available for metabolism. The relationship is CLh = (Qh × fu × CLint) / (Qh + fu × CLint). If fu × CLint is much smaller than Qh, the denominator is effectively Qh, so CLh ≈ (Qh × fu × CLint) / Qh = fu × CLint. This means the liver's capacity to metabolize (intrinsic clearance) is the limiting factor, not the blood flow. Therefore, hepatic clearance is approximately fu × CLint.

SAMPLE

10. Which drug is listed under Other Antibiotics in the material?

A. Amoxicillin

B. Ofloxacin

C. Minocycline

D. Rifampicin

This item tests grouping antibiotics by class and recognizing which drugs fall outside the common class categories. Rifampicin belongs to the rifamycin family, which has a distinct mechanism—inhibiting bacterial DNA-dependent RNA polymerase—and a characteristic PK profile of strong hepatic enzyme induction and autoinduction. Because of its unique mechanism and classification, it is placed in a broad "Other Antibiotics" category in many materials. The other drugs listed—amoxicillin (a beta-lactam penicillin), ofloxacin (a fluoroquinolone), and minocycline (a tetracycline)—fit into their respective well-known antibiotic classes and so appear in those sections rather than in "Other Antibiotics."

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://mdcpk2.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE